ALK inhibitors have emerged in recent years for postoperative targeted therapy in NSCLC patients, in which crizotinib, a small molecule ATP-competitive ALK inhibitor, is widely applied worldwide due to its favorable efficacy and relative safety33,34. This evidence concerns the gene ALK and non-small cell lung carcinoma.